Preliminary data also suggest ibrutinib may enhance the proliferative capacity and efficacy of CAR T cells, possibly through reduced expression of programmed death protein 1 (PD1) on T cells[124-126], and expand host CD8+ subpopulations with cytotoxicity against CLL cells[127]. This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.